Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 15/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4162429 | 0.82 | SLC7A5 (0.37) | — | |
| SCHEMBL4160100 | 0.78 | GRIN2D (0.33) | — | |
| SCHEMBL9111004 | 0.77 | DPP4 (0.41) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL8400951 | 0.77 | DPP4 (0.41) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL1952051 | 0.77 | NOS1 (0.53) | DPP4DPP8DPP9NOS1NOS3 | |
| SCHEMBL1952544 | 0.77 | NOS1 (0.53) | DPP4DPP8DPP9NOS1NOS3 | |
| SCHEMBL1841059 | 0.77 | NOS1 (0.53) | DPP4DPP8DPP9NOS1NOS3 | |
| SCHEMBL6224216 | 0.77 | NOS1 (0.53) | DPP4DPP8DPP9NOS1NOS3 | |
| SCHEMBL4425446 | 0.77 | NOS1 (0.53) | DPP4DPP8DPP9NOS1NOS3 | |
| SCHEMBL919004 | 0.77 | NOS1 (0.53) | DPP4DPP8DPP9NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099307-A1 | Inverse solid phase peptide synthesis with additional capping step | ACTIVOTEC SPP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20080242836-A1 | Convergent Solid Phase Peptide Synthesis By Reaction Of Two Fragments Bound To Solid Support | UNIVERSITY OF SOUTHAMPTON (GB) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099307-A1 | Inverse solid phase peptide synthesis with additional capping step | RNGTT, CPSF7, CPSF1 | DPP4 278/4885DPP8 316/4885DPP9 276/4885 |
| US-20080242836-A1 | Convergent Solid Phase Peptide Synthesis By Reaction Of Two Fragments Bound To Solid Support | CPSF1, CPSF7, MAX | DPP4 2349/4885DPP8 1700/4885DPP9 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.